VIDEO: Novel agents show 'significant trend' toward better responses for relapsed LBCL
Click Here to Manage Email Alerts
In this video, Brian T. Hill, MD, PhD, discusses research that evaluated the effectiveness of chemo-immunotherapy against three novel combination therapies in the second line or later for patients with relapsed/refractory large B-cell lymphoma.
Results from the large, multicenter, real-world comparison study, presented at ASH Annual Meeting and Exposition, showed that novel agents such as loncastuximab tesirine (Zynlonta, ADC Therapeutics), tafasitamab (Monjuvi; MorphoSys, Incyte) and polatuzumab vedotin (Polivy, Genentech) showed “significant trend” toward better responses and longer durability as compared with chemo-immunotherapy, Hill, director of the lymphoid malignancies program at Cleveland Clinic, said.
"The days for sequential lines of therapy for relapsed large B-cell lymphoma should be sort of coming to an end," he said.
"We really should be incorporating the novel agents as either a part of initial therapy with polatuzumab or in subsequent lines and then trying to get some consolidation strategies, either with bispecifics or [chimeric antigen receptor] T-cell therapy," Hill continued.
Reference:
- Nastoupil L, et al. Effectiveness of chemo-immunotherapy (CIT) and novel therapies in second or later line of therapy (2L+) for patients with relapsed/refractory (R/R) aggressive large B-cell lymphoma (LBCL). Presented at: ASH Annual Meeting and Exposition, Dec. 9-12, 2023; San Diego.
Collapse
Healio Interviews
Read more about
Click Here to Manage Email Alerts